Skip to Main Content

Good morning, one and all. Damian Garde here, filling in for Ed Silverman on the eve of a winter storm in our part of the world that could either dust the sidewalk or bring about the end of civilization, depending on which meteorologists you trust. Here’s hoping you’ve got a plan in place to withstand whatever weather the weekend brings — or, even better, that you had the good sense to live some place where catastrophic snowfall is a foreign concept. Anyway, here as always are a few tidbits to get your day started, and please do let us know if you hear anything interesting out there. …

Biogen (BIIB) is selling its stake in a biosimilars joint venture for $2.3 billion, STAT tells us, adding to the company’s cash reserves as investors clamor for M&A. Under the agreement, Samsung Biologics is acquiring Biogen’s roughly 50% stake in the biosimilars manufacturer Samsung Bioepis, which the two founded in 2012.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment